Evondos Group appoints Frans Cromme as CEO to lead next phase of international growth and portfolio expansion

Over the past few years, the Evondos Group has expanded its impact across the Nordics and the Netherlands and has entered the UK market. Evondos Group has successfully dispensed over 100 million medicine doses with adherence rates around 99%, helping save over 800,000 working days for care organizations and ensuring high medication safety for tens of thousands of people every day. The group expanded its offering by joining forces with Medido in 2023 and acquiring Vitacam in 2024.

“Evondos Group exists to enable independent life at home while helping care teams deliver safe, high-quality home care at scale. Frans Cromme brings deep, international healthcare experience to continue that mission and support our teams and customers,” says Niklas Savander, Chair of the Board.

“I’m honored to join Evondos,” says Frans Cromme. “Our focus remains clear: customer centricity and safety in medication dispensing. We will continue to bring solutions to support home care nurses in their daily routines, which is an increasing need with our aging populations. ”

Frans Cromme has a broad background in healthcare and as a MedTech CEO, with experience at ViCentra, Unilabs, Smith & Nephew, and Organon, across multiple locations around the world.

About Evondos

Evondos Group is a European health-tech company providing automated medicine-dispensing services that improve medication safety and support independent living at home. Evondos Group serves more than 500 care organizations across the Nordics and the Netherlands.

Media contact Niko van Eeghen, Chief Product & Marketing Officer, Evondos Group: niko.vaneeghen@evondos.com / +358 44 782 1502

Notes to editors: Evondos Group acquired Medido (Feb 2023) and Vitacam (Aug/Oct 2024). Owner: Verdane.